



Enzymatica
THE SCIENCE THAT PROTECTS

11 April 2022

Non-regulatory press release

Article about ColdZyme acquitted from suspicions of research misconduct

The Swedish National Board for Assessment of Research Misconduct (Npof) has acquitted the two researchers who had been reported by Region Skåne for an article about an Enzymatica financed scientific study. According to Npof, there is no basis for the suspicion of falsification or fabrication of data.

Region Skåne filed a complaint to Npof in December 2021 regarding the article from 2017 about Enzymatica's study Coldprev 1. The board acquits the researchers from the suspicion of research misconduct and states in its decision:

"The board is of the opinion that if you read the article in its entirety, it is clear how the experiments have been carried out and how the calculations have been made. Thus, there is no basis for the suspicion of falsification or fabrication of data" (Npof, Dnr 3.1-21 0177, Enzymatica's translation from Swedish)

"We are not surprised. These are well-reputed researchers who have no reason to push any boundaries. For their and our sake, I hope that Npof's decision now puts an end to this issue", said Claus Egstrand, CEO of Enzymatica.

The study was financed by Enzymatica and results from the study, together with results from a number of other studies, have been used in many regulatory application processes around the world when ColdZyme has been approved by local authorities for new markets. Results from the study were part of the collective clinical data that was assessed when ColdZyme was approved as a class-III medical device in the EU. The three most recent markets where the product has been approved by regulatory bodies are Canada, Mexico, and Turkey.

"We have an effective product with good scientific documentation. This leads to very smooth and fast approval processes for new markets, which allows for us to expand internationally at a good pace", said Claus Egstrand.

FOR MORE INFORMATION, PLEASE CONTACT:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 (0) 708 55 11 85 | Email: stefan.olsson@enzymatica.com

Enzymatica AB develops and sells health care products primarily for conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 4 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit: www.enzymatica.com.